Comparison of Acute Stent Recoil Between the Everolimus-Eluting Bioresorbable Vascular Scaffold and Two Different Drug-Eluting Metallic Stents  by Borghi, Tarcisio Campostrini et al.
Rev Bras Cardiol Invasiva. 
2013;21(4):326-31
© 2013 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. All rights reserved.
Comparison of Acute Stent Recoil Between the 
Everolimus-Eluting Bioresorbable Vascular Scaffold  
and Two Different Drug-Eluting Metallic Stents
Tarcisio Campostrini Borghi Jr.1, J. Ribamar Costa Jr.2, Alexandre Abizaid3, Daniel Chamié4,  
Mateus Veloso e Silva5, Danillo Taiguara6, Ricardo Costa7, Rodolfo Staico8, Fausto Feres9,  
Áurea J. Chaves10, Dimytri Siqueira11, Amanda G. M. R. Sousa12, J. Eduardo Sousa13
ABSTRACT
Background: Bioresorbable vascular scaffolds (BVS) have been 
developed to provide support to the vessel wall during the 
healing process after percutaneous coronary intervention (PCI), 
being resorbed afterwards. Because the scaffold is made of 
polymeric material, there is a concern regarding the acute recoil 
of the device. We compared the BVS acute recoil with that of 
two different metal drug-eluting stents. Methods: Fifty patients 
with non-complex lesions were included. Twenty-five of these 
patients were treated with a BVS who were compared to 25 
patients treated with a cobalt-chromium everolimus-eluting stent 
(EES, n = 12) or a stainless steel biolimus-eluting stent (BES, n 
= 13). Acute recoil was defined as the difference between the 
mean diameter of the balloon during its maximum inflation 
pressure (X) and the mean diameter of the stent immediately 
after balloon deflation (Y). The percentage of acute recoil was 
defined as (X-Y)/X. Results: There was no significant difference 
in the baseline clinical and angiographic characteristics. Acute 
luminal gain was lower with BVS compared to EES and BES 
(1.51 ± 0.41 mm vs. 1.76 ± 0.28 mm vs. 1.9 ± 0.42 mm, P = 
0.02). Acute recoil was 0.21 ± 0.13 mm vs. 0.15 ± 0.08 mm 
vs. 0.14 ± 0.08 mm (P = 0.21) and the percentage of acute 
recoil was 7.0 ± 4.6% vs. 5.0 ± 2.2% vs. 5.7 ± 4.1% (P = 
0.16). Conclusions: BVS presented a slightly higher, although 
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RESUMO
Comparação da Retração Aguda do Stent Entre o 
Suporte Vascular Bioabsorvível Eluidor de Everolimus 
e Dois Diferentes Stents Metálicos Farmacológicos
Introdução: Suportes vasculares bioabsorvíveis (SVB) têm sido 
desenvolvidos como forma de fornecer sustentação à parede 
do vaso enquanto ocorre o processo de cicatrização, após 
a intervenção coronária percutânea (ICP), sendo absorvido 
posteriormente. Pelo fato da plataforma ser de material poli-
mérico, existe preocupação em relação à retração aguda do 
dispositivo. Avaliamos aqui a retração aguda do SVB com a 
de dois diferentes stents farmacológicos metálicos. Métodos: 
Foram incluídos 50 pacientes com lesões não complexas. Dentre 
esses pacientes, 25 foram tratados com SVB e comparados 
a outros 25 pacientes tratados com stent de cromo-cobalto 
eluidor de everolimus (EES; n = 12) ou stent de aço inoxidá-
vel eluidor de biolimus (BES; n = 13). A retração aguda foi 
definida como a diferença entre o diâmetro médio do balão 
durante a pressão máxima de inflação (X) e o diâmetro médio 
do stent após o esvaziamento do balão (Y). A porcentagem 
de retração aguda foi definida como (X – Y)/X. Resultados: 
Não houve diferença significativa em relação às características 
clínicas e angiográficas basais. O ganho luminal agudo foi 
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not significant, acute recoil than the two second-generation 
metallic drug-eluting stents.
 
 
 
 
 
 
DESCRIPTORS: Percutaneous coronary intervention. Drug-
-eluting stents. Absorbable implants. Coronary angiography.
Dante Pazzanese de Cardiologia, São Paulo, Brazil. 
The study population was composed of patients treated 
with ABSORB® BVS, BioMatrix®, and Xience V®, as part 
of local protocols developed in this institution. Some 
inclusion criteria were adopted in the present analysis 
in order to approximate the cohorts and minimize po-
tential biases. Only patients with single de novo lesions 
between 70 and 90% (visual determination), in native 
coronaries with a diameter between 2.5 and 3.5 mm, 
were included. The maximum permitted length of the 
lesion was 23 mm. As a common feature for the entire 
group, only patients electively treated were included, 
and those with target lesion in left main coronary artery, 
ostial lesions, lesions with thrombi, lesions with exces-
sive calcification requiring athero-ablative techniques 
before the device implantation, and bifurcation lesions 
with lateral branch > 2 mm were excluded.
Devices used
The ABSORB® BVS has a platform composed of 
poly-L-lactic acid (PLLA), everolimus, an antiprolif-
erative drug, and a delivery system. The BVS body is 
coated by the matrix of poly-D, L-lactic acid (PDLLA) 
and everolimus in a 1:1 ratio. PLLA and PDLLA are 
completely metabolized and absorbed by the organism.
The Xience V® stent is composed by a balloon-
expandable platform MULTI-LINK VISION® with ser-
pentine rings connected by links and manufactured 
from a single piece of chrome-cobalt coated with a 
durable polymer containing everolimus. The thickness 
of the rods is 0.081 µm.
The BioMatrix® stent incorporates the S-stent platform, 
a laser-cut stainless steel tubular stent with rods measur-
ing 112 µm. The antiproliferative drug used is biolimus 
A9, a semisynthetic and highly lipophilic analogue of 
sirolimus. Based on in vivo trials, the biodegradable 
polymer of polylactic acid (PLA) is completely converted 
into lactic acid in six to nine months.
Procedure
All procedures were performed electively, in accordance 
with current guidelines. The lesions were treated with 
menor com o SVB comparado ao EES e ao BES (1,51 ± 0,41 
mm vs. 1,76 ± 0,28 mm vs. 1,9 ± 0,42 mm; P = 0,02). A 
retração aguda foi de 0,21 ± 0,13 mm vs. 0,15 ± 0,08 mm 
vs. 0,14 ± 0,08 mm (P = 0,21), e o porcentual de retração 
aguda foi de 7,0 ± 4,6% vs. 5,0 ± 2,2% vs. 5,7 ± 4,1% (P 
= 0,16). Conclusões: O SVB demonstrou ter retração aguda 
ligeiramente maior, embora não significativa, que os stents 
metálicos farmacológicos de segunda geração. 
DESCRITORES: Intervenção coronária percutânea. Stents 
farmacológicos. Implantes absorvíveis. Angiografia coronária.
D rug-eluting stents are the devices of choice for percutaneous treatment of coronary artery disease (CAD). These devices provide support to the 
artery walls, preventing acute and delayed retraction 
of the vessel, and inhibit in-stent intimal proliferation. 
As a consequence, the use of these devices leveraged 
the success rates of the procedure and allowed for the 
achievement of lasting results.1
However, the definitive permanence of the stents’ 
metal rods, with the consequent imprisonment of the 
vessel, can cause changes in motor function and re-
modelling (Glagov phenomenon), leading to a poor 
apposition of the rods and to changes in the vessel 
conformability.2
In the last decade, the idea of a transitory vascular 
scaffold, which, for a certain period, might modulate 
a reparative intimal hyperplasia and, at the same 
time, would avoid the remodelling of the target artery, 
being then resorbed, has gained prominence in the 
area of percutaneous approach of coronary diseases. 
Bioresorbable vascular scaffolds (BVS), also commonly 
called “bioresorbable stents,” would be devices that 
would meet these requirements. However, a major dif-
ficulty in developing such devices, especially those of 
polymeric composition, would be to confer sufficient 
radial force to prevent the occurrence of acute and 
delayed retraction of the vessel, not uncommon in 
the first prototypes.3
Among the most developed BVS clinical programs, 
the ABSORB® (Abbott Vascular, Santa Clara, United 
States), which combines a polymer platform with evero-
limus, an antiproliferative drug, stands out favorably. 
The present study aimed to compare the acute recoil 
of ABSORB® BVS with the observed recoil of cobalt-
chromium (Xience® V; Abbott Vascular – Santa Clara, 
United States) and stainless steel (BioMatrix®; Biosensors 
International – Singapore) metal stents.
METHODS
Study design and target population 
This was a retrospective, single-center trial, developed 
at the Department of Invasive Cardiology of Instituto 
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standard intervention techniques, which included manda-
tory pre-dilation with a shorter balloon with a diameter 
0.5 mm smaller than the device used. Post-dilation, when 
performed (at the discretion of the operator), should have 
been performed with noncompliant balloons at least 30% 
shorter than the BVS or stent implanted.
The preprocedural dual antiplatelet therapy con-
sisted of acetylsalicylic acid 100 to 200 mg/day and a 
loading dose of clopidogrel 300 mg, at least 24 hours 
before the procedure, or 600 mg if < 24 hours. After 
the intervention, acetylsalicylic acid 100 to 200 mg/
day was prescribed indefinitely, and clopidogrel 75 
mg/day was maintained for at least six months. Dur-
ing the percutaneous coronary intervention (PCI), the 
antithrombin therapy consisted of unfractionated heparin 
at a dose of 100 IU/kg (or 70 IU/kg in the case of 
administering glycoprotein IIb/IIIa inhibtor), aiming to 
achieve an activated clotting time > 250 s (or between 
200 and 250 s if using glycoprotein IIb/IIIa inhibtor).
Quantitative coronary angiographic analysis 
The pre- and post-procedural angiographies were 
obtained after the administration of intracoronary nitro-
glycerin (50 to 200 mg) in at least two corresponding 
orthogonal projections, which were stored in DICOM 
format for digital off-line analysis. The quantitative coro-
nary angiographic (QCA) analysis was performed with a 
dedicated computer program, with semi-automatic lumen 
border detection (QAngio XA version 7.3; Medis Medical 
Imaging System – Leiden, the Netherlands). The qualitative 
and quantitative angiographic analyzes were performed 
by two experienced operators, following a predefined 
protocol. The tip of the guide catheter filled with contrast 
was used for calibration. The minimal lumen diameter 
(MLD) and the reference diameter (RD), obtained by in-
terpolation, were used to calculate the stenosis diameter: 
SD = (1 – MLD/RD) × 100. Acute recoil was defined as 
the difference between the mean diameter of the balloon 
during maximum pressure of inflation (X) and the mean 
intra-stent lumen diameter immediately after the deflation 
of the balloon (Y); the percentage of acute recoil was 
defined as (X – Y)/X (Figure).
Statistical analysis
Categorical variables were presented as frequen-
cies and percentages, and compared by means of an 
analysis of variance (ANOVA) test. Continuous variables 
were presented as mean and standard deviation, and 
compared using the nonparametric Kruskal-Wallis test. 
P-values < 0.05 were considered statistically significant. 
The statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS) software version 
19 for Windows (Chicago, IL).
RESULTS
Clinical characteristics
The present study evaluated 50 patients undergoing 
elective angioplasty; 25 treated with BVS, 12 treated with 
EES, and other 13 with BES. The clinical characteristics 
are summarized in Table 1. There was no significant dif-
ference between the clinical variables analyzed, except 
for a higher prevalence of previous myocardial infarction 
in the groups treated with bare-metal stents (P = 0.01).
Angiographic and procedural variables
The pre- and post-intervention angiographic variables 
are summarized in Table 2. The most approached ves-
sel in the group treated with AVS was the left anterior 
descending artery, whereas in patients treated with metal 
stents the vessel most approached was the left circumflex 
artery (P = 0.24). There was no significant difference be-
tween groups in relation to vessel RD (2.62 ± 0.45 mm 
vs. 2.73 ± 0.36 mm vs. 2.49 ± 0.44 mm; P = 0.34) or 
length of lesions (11.7 ± 4.0 mm vs. 3.4 mm vs. 10.1 ± 
12.9 ± 5.9 mm; P = 0.31). The pre-procedural MLD was 
not different between the groups (0.87 ± 0.32 mm vs. 
0.90 ± 0.25 mm vs. 0.78 ± 0.44 mm; P = 0.52); after 
the procedure, the patients treated with BVS had lower 
MLD (2.39 ± 0.31 vs. 2.66 ± 0.26 mm vs. 2.69 mm ± 
TABLE 1 
Clinical characteristics
BVS 
(n = 25)
EES 
(n = 12)
BES 
(n = 13) P-value
Age, years 56.8 ± 7.0 59.8 ± 10.3 61.0 ± 4.8 0.33
Male, n (%) 15 (60) 6 (50) 9 (69.2) 0.39
Diabetes, n (%) 5 (20) 0 1 (57.7) 0.28
Hypertension, n (%) 19 (76) 9 (75) 11 (84.6) 0.82
Dyslipidemia, n (%) 19 (76) 8 (66.7) 8 (61.5) 0.66
Smoking, n (%) 3 (12) 1 (8.3) 3 (23.1) 0.57
Previous myocardial infarction, n (%) 5 (20) 7 (58.3) 8 (61.5) 0.01
BVS = bioresorbable vascular scaffold; EES = everolimus-eluting stent; BES = biolimus-eluting stent.
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0.45 mm; P < 0.03). The acute gain was lower with BVS 
(1.51 ± 0.41 vs. 1.76 ± 0.28 mm vs. 1.9 ± 0.42 mm; P 
= 0.02). The maximum inflation pressure of the balloon 
in post-dilation was intermediate for BVS (16.7 ± 4.0 
atm vs. 15.0 ± 7.1 atm vs. 19.1 ± 3.8 atm; P = 0, 03), 
as the balloon: artery ratio (1.08 ± 0.14 vs. 1.05 ± 0.11 
vs. 1.16 ± 0.12; P = 0.06).
Evaluation of acute stent recoil
The angiographic parameters related to the evaluation 
of acute recoil are shown in Table 3. Acute recoil and 
percentage of acute recoil were numerically higher in 
the group treated with BVS compared with patients who 
received metal stents (EES and BES), but this difference 
did not reach statistical significance (0.21 ± 0.13 mm 
vs. 0.15 ± 0.08 mm vs. 0.14 ± 0.08 mm; P = 0.21; 
and 7.0 ± 4.6% vs. 5.0 ± 2.2% vs. 5.7 ± 4.1%; P = 
0.16, respectively, for BVS, EES, and BES).
Relation of angiographic and procedural 
variables to the percentage of acute stent recoil
Table 4 lists the relationship of angiographic and 
procedural variables to the percentage of acute recoil. 
The balloon: artery ratio ≥ 1.1 presented higher percent-
age of acute recoil in the BVS group (P = 0.05). The 
other variables were not correlated with the occurrence 
of acute stent recoil.
DISCUSSION
The main finding of this study was that the ABSORB® 
BVS presented a slightly higher acute recoil, compared 
to two second-generation metal stents, although not 
statistically significant. 
One of the benefits of metal stents is to provide an 
adequate vascular scaffold, preventing acute occlusion 
as well as acute and delayed retraction of the vessel. 
This property is required during the healing phase of the 
target segment, later making the device unnecessary. The 
permanent presence of a metal stent can interfere with 
the vessel’s motor function and remodelling, and the 
device can permanently imprison the vessel, preventing 
surgical revascularization in cases where there is need 
to treat long segments (full metal jacket). In addition, 
the metal stent can imprison secondary branches and 
compromise the carrying out of noninvasive images of 
the coronary arteries, such as angiotomography and MRI.2
BVS were designed with the purpose of providing a 
transitional vascular scaffold in the critical healing phase 
after PCI and, at the same time, promoting modulation 
of the restorative intimal hyperplasia through the release 
of antiproliferative drugs. As the bioresorbable platforms 
are more flexible than those made of metal, there is 
concern whether these new devices would provide the 
same radial force as offered by metal platforms. Previ-
ous clinical trials that evaluated the post-implant rate 
TABLE 2 
Angiographic and procedural variables
BVS
(n = 25)
EES
(n = 12)
BES
(n = 13) P value
Treated vessel, n (%) 0.24
LAD 13 (52) 3 (25.0) 4 (30.8)
LCx 4 (16) 5 (41.7) 6 (46.2)
RCA 8 (32) 4 (33.3) 3 (23.1)
Lesion length, mm 11.7 ± 4.0 10.1 ± 3.4 12.9 ± 5.9 0.31
Reference diameter, mm 2.62 ± 0.45 2.73 ± 0.36 2.49 ± 0.44 0.34
Stenosis diameter, % 
Pre 66.7 ± 10.5 67.7 ± 9.2 70.0 ± 13.0 0.79
Post 8.4 + 4.0 8.2 ± 4.2 5.6 + 2.5 0.58
Minimal luminal diameter, mm 
Pre 0.87 ± 0.32 0.90 ± 0.25 0.78 ± 0.44 0.52
Post 2.39 ± 0.31 2.66 ± 0.26 2.69 ± 0.45 0.03
Acute gain, mm 1.51 + 0.41 1.76 ± 0.28 1.9 + 0.42 0.02
Maximum inflation pressure of the balloon, post-dilation, atm 16.7 ± 4.0 15.0 ± 7.1 19.1 ± 3.8 0.03
Balloon:artery ratio 1.08 ± 0.14 1.05 ± 0.11 1.16 ± 0.12 0.06
LAD = left anterior descending artery; LCx = left circumflex artery; RCA = right coronary artery; BVS = bioresorbable vascular scaffold; 
EES = everolimus-eluting stent; BES = biolimus-eluting stent.
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of acute recoil of non-pharmacological metal stents 
demonstrated a variation between 3% and 15%.4-7 This 
wide variation in rates of acute recoil was attributed, 
in part, to stent material and design, and also to the 
difference in the definitions of acute recoil.
The idea of BVS devices is not innovative, 
since various types of models have been tested in 
experimental trials. The Igaki-Tamai stent was the 
first bioresorbable device tested in humans in the 
late 90s.8 Its platform, which consisted of PLLA, had 
no antiproliferative drug in its composition. In this 
pioneering work, the rate of acute recoil was 22%, 
and the author used a different methodology from 
that employed in the present trial.
More recently published trials that used the same 
methodology, comparing the acute recoil of BVS with 
that of second-generation metal stents, showed results 
similar to those of the present study. Tanimoto et al.9 
compared BVS with EES and found that the percent-
age of acute recoil was 6.9 ± 7.0% in BVS group and 
4.3 ± 7.1% in EES group (P = 0.25). Onuma et al.10 
compared the acute recoil of two versions of ABSORB® 
BVS (revision 1.0 and revision 1.1) with XIENCE V® 
stent, and observed that the acute recoil of BVS 1.1 
was slightly higher when compared to metal EES (EES: 
4.3 ± 7.1%; BVS 1.0: 6.9 ± 7.0%; BVS 1.1: 6.7 ± 
6.4%; P = 0.22). Recently, acute recoil data of another 
BVS, the DESolve, were presented, also showing good 
radial force and an acute recoil of 6.4 ± 4.6%.11 The 
third BVS tested was DREAMS® (Biotronik – Bülach, 
Switzerland); its structure is composed of magnesium, 
and the antiproliferative drug used is paclitaxel. This 
device was assessed in the first-in-man BIOSOLVE-I 
TABLE 3 
Angiographic parameters related to acute stent recoil
BVS
(n = 25)
BES
(n = 13) P-value
Diameter of the balloon at its maximum inflation pressure, mm 2.82 ± 0.32 3.09 ± 0.42 0.11
Stent diameter after balloon deflation, mm 2.60 ± 0.31 2.95 ± 0.41 0.18
Acute recoil, mm 0.21 ± 0.13 0.14 ± 0.08 0.21
Acute recoil,% 7.0 ± 4.6 5.7 ± 4.1 0.16
BVS = bioresorbable vascular scaffold; EES = everolimus-eluting stent; BES = biolimus-eluting stent.
TABLE 4 
Relation of angiographic and procedural variables with percentage of acute stent recoil
BVS EES BES
P-valuen Recoil (%) n Recoil (%) n Recoil (%)
RVD, mm
≥ 3.0 6 6.6 ± 1.4 3 5.2 ± 3.9 3 3.7 ± 3.4 0.61
< 3.0 19 7.8 ± 5.2 9 4.9 ± 1.3 10 4.4 ± 2.4 0.21
P-value > 0.99 0.60 > 0.99
Maximum pressure, atm
> 16 5 9.4 ± 5.8 7 5.1 ± 2.7 10 4.5 ± 2.5 0.51
≤ 16 20 7.0 ± 4.2 5 4.8 ± 1.2 3 3.2 ± 2.8 0.17
P value 0.82 0.88 0.46
Balloon:artery ratio
≥ 1.1 10 9.6 ± 5.3 4 5.1 ± 1.5 8 3.6 ± 2.5 0.05
< 1.1 15 6.1 ± 3.5 8 4.9 ± 2.5 5 5.2 ± 2.6 0.76
P-value 0.09 0.93 0.35
BVS = biosorbable vascular scaffold; EES = everolimus-eluting stent; BES = biolimus-eluting stent; RVD = reference vessel diameter.
Borghi et al. 
Acute Retraction SVB vs. Metallic Stents
Rev Bras Cardiol Invasiva. 
2013;21(4):326-31
331
trial, demonstrating good performance with respect to 
acute recoil (9.19 ± 7.23%).12
Since the acute recoil results from the balance 
between the elastic recoil of the vessel wall and the 
radial force of the stent, this relation may be changed 
by the characteristics of the lesion or by the proce-
dure itself; for instance, the reference vessel diameter, 
the maximum inflation pressure of the balloon, and 
an oversizing of the stent used. In relation to vessel 
diameter and the maximum inflation pressure of the 
balloon, there was no difference in rates of recoil 
among the three groups. However, in the group of 
patients who had a relation balloon: artery ≥ 1.1, 
there was a greater rate of recoil in BVS (P = 0.05). 
These results highlight the importance of a properly 
sizing of the vessel and, possibly, preparing the injury 
prior to the implantation of BVS.
The present study had some limitations, since it 
was conducted in a single center; besides, it was a 
nonrandomized trial with a small number of patients. 
Furthermore, the results can also be related to the 
inclusion, in the analysis, of low complexity lesions.
CONCLUSIONS
In this casuistry, the ABSORB® BVS demonstrated 
good radial force with a slightly higher, although not 
significant, acute recoil, compared to second genera-
tion metal stents. Studies with more patients and in 
more complex scenarios are needed to confirm these 
preliminary observations.
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